Endo Pharmaceuticals (NASDAQ: ENDP ) This specialty pharma company develops
branded and generic prescription drugs used primarily to treat and manage pain
and urologic disorders. Its recent acquisitions led fundamental analysts to
project a 17% increase in revenues for 2012. And its entry into new therapeutic
areas will benefit the company in the future.
No comments:
Post a Comment